Goichot Bernard, Bouée Stéphane, Castello-Bridoux Claire, Caron Philippe
Department of Internal Medicine, Endocrinology and Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
FMTS, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.
Eur Thyroid J. 2017 Jul;6(3):152-159. doi: 10.1159/000453260. Epub 2017 Jan 5.
Considerable variations in diagnosis and therapeutic practices are reported for hyperthyroidism (HT) between countries.
A clinical study was conducted among a representative sample of 263 endocrinologists in France. All consecutive patients seen for HT during the study period were included. Diagnosis and treatment modalities were recorded from hyperthyroid patients with Graves disease (GD, = 802), multinodular goiter (MNG, = 121), and toxic adenoma (TA, = 69).
Antithyroid antibodies were measured in half of the population (anti-TPO in 48.5% and anti-TSH receptor in 57.8%). Patients had thyroid ultrasonography and scintigraphy in 93.8 and 40.3%, respectively. Therapeutic management depended on the etiology: for the first episode of GD, antithyroid drugs (ATDs) were the first-line treatment in 91% of the patients, combined with surgery in 6.1% and with radioiodine in 2.9%. Surgery was preferred to radioiodine in MNG (52.6 vs. 22.4%) and TA (59.1 vs. 24.2%). Euthyroid status was achieved after 3 months in 64.4% of GD. A "block and replace" protocol was used in 41.2% of patients. After 3 months, 73% of patients were euthyroid in the "block and replace" group compared to 56.2% in the group with ATDs alone ( = 0.009). For MNG and TA, more than 75% of patients were euthyroid at the 3-month follow-up.
Large discrepancies remain between clinical practice and international guidelines. These results should boost efforts to improve adherence to these guidelines.
据报道,各国在甲状腺功能亢进症(HT)的诊断和治疗方法上存在很大差异。
对法国263名内分泌科医生的代表性样本进行了一项临床研究。纳入了研究期间所有连续就诊的HT患者。记录了格雷夫斯病(GD,n = 802)、多结节性甲状腺肿(MNG,n = 121)和毒性腺瘤(TA,n = 69)所致甲状腺功能亢进患者的诊断和治疗方式。
一半的患者检测了抗甲状腺抗体(48.5%检测了抗甲状腺过氧化物酶抗体,57.8%检测了促甲状腺激素受体抗体)。分别有93.8%和40.3%的患者进行了甲状腺超声检查和闪烁扫描。治疗方案取决于病因:对于GD的首次发作,91%的患者一线治疗采用抗甲状腺药物(ATD),6.1%的患者联合手术治疗,2.9%的患者联合放射性碘治疗。MNG(52.6%对22.4%)和TA(59.1%对24.2%)患者中,手术治疗比放射性碘治疗更受青睐。64.4%的GD患者在3个月后甲状腺功能恢复正常。41.2%的患者采用了“阻断并替代”方案。3个月后,“阻断并替代”组73%的患者甲状腺功能恢复正常,而单纯使用ATD组为56.2%(P = 0.009)。对于MNG和TA,超过75%的患者在3个月随访时甲状腺功能恢复正常。
临床实践与国际指南之间仍存在很大差异。这些结果应促使人们加大努力以提高对这些指南的遵循程度。